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Abstract
Objective: To assess the efficacy and safety of sono-electro-magnetic therapy
compared to placebo in men with refractory CPPS.
Patients and Methods: In a randomized, placebo-controlled, double-blind single
center trial, we assessed the effect of sono-electro-magnetic therapy in men with
treatment refractory CPPS. Sixty male patients were randomly assigned to
treatment with either sono-electro-magnetic (n530) or placebo therapy (n530) for
12 weeks. The primary outcome was a change in the National Institutes of Health
Chronic Prostatitis Symptom Index (NIH-CPSI) from baseline to 12 weeks.
Results: The 12-week difference between sono-electro-magnetic and placebo
therapy in changes of the NIH-CPSI total score was 23.1 points (95% CI 26.8 to
0.6, p50.11). In secondary comparisons of NIH-CPSI sub-scores, we found
differences between groups most pronounced for the quality-of-life sub-score
(difference at 12 weeks 21.6, 95% CI 22.8 to 20.4, p50.015). In stratified
analyses, the benefit of sono-electro-magnetic therapy appeared more pronounced
among patients who had a symptom duration of 12 months or less (difference in
NIH-CPSI total score 28.3, 95% CI 214.5 to 2.6) than in patients with a longer
symptom duration (20.8, 95% CI 24.6 to 3.1; p for interaction50.023).
Conclusions: Sono-electro-magnetic therapy did not result in a significant
improvement of symptoms in the overall cohort of treatment refractory CPPS
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patients compared to placebo treatment. Subgroup analysis indicates, however,
that patients with a symptom-duration of 12 months or less may benefit from sono-
electro-magnetic therapy, warranting larger randomized controlled trials in this
subpopulation.
Trial Registration: ClinicalTrials.gov NCT00688506
Introduction
Male chronic pelvic pain syndrome (CPPS), also called chronic prostatitis, is a
disabling disorder characterized by a non-malignant pain in the pelvic region that
lasts for at least three months without evidence of infection or other obvious
pathology [1]. Approximately 6%–12% of men suffer from CPPS; the disease
affects millions worldwide [2]. It is similar to congestive heart failure, Crohn’s
disease, diabetes mellitus or angina [3] in lowering quality of life, and represents a
serious economic burden on any health care system. Associated costs match those
reported for peripheral neuropathy, low back pain, fibromyalgia, and rheumatoid
arthritis [4].
Factors contributing to CPPS may include chemical irritants, pelvic floor
muscle irregularities, and immunological, endocrine and neurological dysfunc-
tion. Presumptive triggers are many, and therapeutic approaches are both varied,
and of limited effect [5]. Multimodal therapies are more successful than single
therapies, and a combination of antibiotics, alpha-blockers and/or anti-
inflammatories seems to help some patients [6, 7]. However, approximately 20%
to 65% of all patients find no relief in conventional therapies [6, 8] and treatment
of CPPS remains a challenge. Effective, easy to tolerate therapeutic alternatives are
urgently needed.
Neuromodulative techniques, based on the theory of pain sensitization via
descending and ascending pathways, have become increasingly popular for
treating chronic pain, and have had promising results [9–11]. A pilot study that
treated patients using a combination of different kinds of neuromodulation
reported encouraging findings [12]. Thus, we performed a single-center,
randomized, placebo-controlled, double-blind trial to assess the effect of the non-
invasive sono-electro-magnetic therapy for treating men with refractory CPPS in
reducing symptoms as measured by the National Institutes of Health Chronic
Prostatitis Symptom Index (NIH-CPSI).
Patients and Methods
2.1. Patients
Potential trial participants were recruited between November 2009 and July 2012
from the urological outpatient clinic at Bern University Hospital, Switzerland. In
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accordance with the EAU guidelines [1], all patients with CPPS included in the
trial complained about pain perceived in pelvic structures for at least three
months, without evidence of infection or other obvious pathologies. All patients
considered for enrolment had complete urological evaluation, including duration
of symptoms, physical examination, urinalysis, determination of prostate-specific
antigen (PSA), free uroflowmetry and post void residual measurement. Included
patients had been unsuccessfully treated with stepwise, multimodal therapy
including the administration of doxycycline (treatment duration of at least four
weeks in patients and two weeks in sexual partners), non-steroidal anti-
inflammatory drugs and alpha-blocker therapy for at least six weeks. Patients had
to have a NIH-CPSI total score $15 and NIH-CPSI pain sub-score $8. Exclusion
criteria were chronic bacterial prostatitis (based on Meares-Stamey 3-glass test
and post-prostatic massage urine culture), urinary tract infection (presence of
bacteria in urinalysis), post void residual.100 mL, prostate cancer, urethral
stricture, and age ,18 years.
2.2. Trial design, treatment and follow-up
The protocol for this trial and supporting CONSORT checklist are available as
supporting information; see S1 CONSORT Checklist and S1 Protocol. After the
baseline examination, patients were randomly allocated to sono-electro-magnetic
or placebo therapy based on computer-generated random numbers with a
randomization ratio of 1:1 and a block size of 60. The manufacturer pre-packed
and sequentially numbered the active and placebo devices according to the
concealed randomization schedule. Active and placebo devices were both
produced by the same manufacturer. They looked identical, were packed
identically, and the placebo device lit the same buttons when charged and when
switched on as the verum device, but did not provide stimulation. Study nurses
handed over the closed packs in sequential order and instructed patients on the
use of the device. Patients, recruiting investigators, study nurses and physicians
performing follow-up assessments were all unaware of the allocated treatment.
Patients performed sono-electro-magnetic and placebo therapy at home, using the
portable Sonodyn device (Sonodyn Corporation AG, Solothurn, Switzerland).
They used a gel and applied the device on the perineum daily in the morning and
evening, for the duration of ten minutes each time. Considering that there are no
high-evidence level studies on the ideal neuromodulation parameters in CPPS, the
devices for sono-electro-magnetic therapy were set to the manufacturer’s
recommended and preset stimulation parameters for treating musculoskeletal
pain: ultrasound intensity of ,100 mW/cm2 with an ultrasonic power of 12 mW
and a frequency of 1.9 MHz, electric field force of ,3 V/m and magnetic field
force of 0.4 A/m. Patients could not see the settings and could not perceive the
device working because it used subsensory stimulation.
Follow-up assessments were performed at 6 and 12 weeks, with an extended
follow-up at 16 weeks. At each time-point, patients received a urological
examination, NIH-CPSI, free uroflowmetry, post void residual, urinalysis and
Sono-Electro-Magnetic Treatment of Chronic Pelvic Pain Syndrome
PLOS ONE | DOI:10.1371/journal.pone.0113368 December 29, 2014 3 / 12
PSA measurement. During the 12-week visit, therapy was halted and the
stimulation device was collected. Adherence to treatment was assessed using a
patient diary, requiring patients to record daily whether they had used the device
in the morning and evening.
2.3. Outcomes
The pre-specified primary outcome was the between-group difference in the
change of total NIH-CPSI score from baseline to 12 weeks. Secondary outcomes
were between-group differences in changes of total NIH-CPSI at 6 and 16 weeks,
and differences in changes of pain, symptom and quality-of-life sub-scores of the
NIH-CPSI at 6, 12 and 16 weeks. As safety parameters, we included voided
volume, post void residual, urinalysis, and PSA at 6, 12, and 16 weeks. In addition,
we used the National Cancer Institute CTCAE version 4 to categorize adverse
effects with grades from 1–5 [13].
2.4. Ethics statement
The study was approved by the local ethics committee (Kantonale
Ethikkommission Bern/3010 Bern/Switzerland/Nummer 292-07) and registered
with ClinicalTrials.gov (trial registration number NCT00688506). All participants
provided written informed consent before inclusion in the trial. The study
conforms to the CONSORT statement (www.consort-statement.org).
2.5. Statistical analysis
This was a superiority trial. Assuming a standard deviation of 6 points for the
NIH-CPSI total score and 10% losses to follow-up, we estimated that 30 patients
per group would provide more than 80% power for an analysis of covariance
adjusted for baseline values to detect a difference between groups of 4 points on
the NIH-CPSI total score [14] at 12 weeks at a two-sided alpha of 0.05. Four
points are associated with 90% sensitivity and 60% specificity to detect treatment
response [14] and were used in previous trials to distinguish responders from
non-responders [5, 14, 15]. The primary analysis was by intention-to-treat,
including all randomly assigned patients in the group to which they were
originally allocated to. For all continuous outcomes, we used an analysis of
covariance adjusted for baseline values [16]. We then stratified the analysis of the
primary outcome according to age (,50 or $50 years), symptom severity (#25
or.25 points on the NIH-CPSI total score), symptom duration (#12 or.12
months), and maximum flow rate (,15 or $15 mL/s), and performed formal
tests of interaction between treatment and subgroup [17]. Finally, we calculated
risk ratios of treatment response and corresponding numbers-needed-to-treat to
achieve one treatment response defined as a decrease in 4 points on the NIH-CPSI
total score. P values are two-sided. We used Stata Release 12 (StataCorp, College
Station, TX) for all analyses.
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Results
3.1. Study participants
Between November 2009 and July 2012, 1342 men with potential CPPS were seen
at our outpatient clinic and 540 were considered for inclusion into the trial. Of
these, 148 were found to be ineligible not fulfilling the inclusion criteria, 258
refused to participate, 74 could not be included for organisational or logistical
reasons. 60 eligible patients gave consent and were eventually randomized to
active device (n530) or placebo device (n530). All patients completed 12 weeks
of follow-up. One patient in the active group withdrew because his symptoms
grew worse after 12 weeks of treatment and completed 12 weeks follow-up but did
not attend the 16-week visit (Fig. 1). Data on adherence to treatment was
available for 45 patients. 37 patients (82%) completed 90% or more of all
treatment sessions. Baseline characteristics of randomized patients are presented
in S1 Table.
3.2. NIH-CPSI
Fig. 2 presents comparisons between groups of NIH-CPSI total and sub-
scores. For the primary outcome of the NIH-CPSI total score at 12 weeks,
there was a decrease from 25.8 to 19.0 with the active device and from 25.2 to
21.8 with the placebo device. Accordingly, the difference in changes was 23.1
points (95% CI 26.8 to 0.6, p50.11). In the analysis of treatment responders
at 12 weeks, we found 21 responders in the active group (70%) and 15
responders in the placebo group (50%) who experienced a clinically relevant
decrease of at least four points on the NIH-CPSI total score (risk ratio 1.40,
95% CI 0.91 to 2.15, p50.11). The corresponding NNT was 5 (95% CI NNT 2
to NNH 23).
In secondary comparisons of NIH-CPSI sub-scores, we found differences
between groups most pronounced for the quality-of-life sub-score (difference at
12 weeks 21.6, 95%-CI 22.8 to 20.4, p50.015), followed by the pain sub-score
(difference at 12 weeks 21.2, 95%-CI 23.3 to 0.8, p50.24). For the urinary
symptoms sub-score, we found little evidence for a difference between groups
(difference at 12 weeks 20.2, 95%-CI 21.3 to 0.9, p50.70 (Fig. 2).
Fig. 3 presents results from stratified analyses of the primary outcome at 12
weeks according to patient characteristics. Effects varied across most subgroups to
an extent compatible with chance variation. However, the benefit of the active
device appeared more pronounced in patients who had a symptom duration of 12
months or less (difference between active and placebo device28.3, 95%-CI 214.5
to 2.6) than in patients with a longer duration of symptoms (difference 20.8,
95%-CI 24.6 to 3.1; p50.023 for interaction between treatment and subgroup).
3.3. Safety parameters and adverse events
Differences in maximum flow rate, voided volume, post void residual, and PSA
are presented in S2 Table. One out of 13 analyses yielded a significant difference
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at p50.038, with a somewhat lower post void residual in patients allocated to the
active device at 6 weeks. One patient in the active group reported a worsening of
symptoms at 12 weeks (3.3%), no other adverse events were reported.
Fig. 1. CONSORT flow diagram. Not reaching the cut-off values for study inclusion in NIH-CPSI total score was the most common reason for ineligibility.
Most subjects who declined to participate considered the treatment as being too cumbersome or were not bothered enough by symptoms.
doi:10.1371/journal.pone.0113368.g001
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Discussion
4.1. Main findings
In this randomized trial in men with treatment refractory CPPS, the decrease in
NIH-CPSI total score was more pronounced with sono-electro-magnetic therapy
than with placebo. The observed difference of 3 points corresponds to an effect
size of 0.5 to 0.6 standard deviations and is likely to be clinically relevant [18]
despite its lack of statistical significance. The notion of clinical relevance is also
reflected by the calculated NNT of 5, which is certainly important in view of the
lack of effective therapeutic alternatives. For the quality-of-life sub-score as one of
our pre-specified secondary outcomes, between-group differences formally
reached statistical significance at 12 weeks (p50.01). In addition, the benefit of
sono-electro-magnetic therapy was significantly (p50.023) more pronounced
among patients with short symptom duration, i.e. #12 months.
Fig. 2. Means and 95% CI for NIH-CPSI total and sub-scores. Higher NIH-CPSI scores indicate more severe symptoms. Score ranges are as follows:
total score 0 to 43; pain sub-score 0 to 21; urinary symptoms sub-score 0 to 10; quality-of-life sub-score 0 to 12. CI: confidence interval; NIH-CPSI: National
Institutes of Health Chronic Prostatitis Symptom Index.
doi:10.1371/journal.pone.0113368.g002
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4.2. Findings in the context of existing evidence
According to the gate control theory, there is a gateway in the dorsal horn of the
spinal cord controlling and/or regulating the flow of nociceptive information. If
appropriately stimulated, it may result in a reduction of pain perception [19].
Additional pain reduction may result from the promotion of endorphin release in
the brain via neuromodulation [20] and other mechanisms [21].
Growing evidence supports a role of the central nervous system during the
initiation and maintenance of pain perception in the absence of distinct peripheral
triggers. Chronic pelvic pain may leave specific imprints in the brain, which in
turn might predispose to CPPS [22, 23]. Spinal cord stimulation is frequently used
to deliver electrical signals to the spinal cord by electrodes in the epidural space to
stimulate nerve fibers. Peripheral neuromodulation is less frequently used, but is
likely to recruit a larger number of nerve fibers due to a wider activation of
inhibitory interneurons [24].
Electroacupuncture was found to be superior to sham electroacupuncture or
exercise alone in a small randomized trial [25]. Although sacral neuromodulation
[26] is a widely accepted therapy for patients with refractory non-obstructive
Fig. 3. Stratified analysis according to patient characteristics. Stratified analysis of the primary outcome (NIH-CPSI total score, range 0 to 43) according
to patient characteristics. CI: confidence interval; NIH-CPSI: National Institutes of Health Chronic Prostatitis Symptom Index.
doi:10.1371/journal.pone.0113368.g003
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chronic urinary retention, urgency-frequency syndrome and urgency incon-
tinence, the value as a treatment for CPPS is unclear [27]. Nevertheless, a
retrospective analysis suggested that sacral neuromodulation is more effective in
patients with a short duration of symptoms [28], which is in line with our
findings of more beneficial results for sono-electro-magnetic therapy in patients
with a symptom duration of #12 months. Finally, in a small single-blind,
crossover trial, invasive pudendal neuromodulation was more effective than sacral
neuromodulation for treating patients with CPPS [29].
4.3. Limitations
The major limitation of our trial is a relative small sample size, which led to
limited power in detecting between group differences smaller than 4 points on the
NIH-CPSI total score. Moreover, including only patients with refractory CPPS
may induce a negative selection bias. Indeed, the treatment effect may be
underestimated in the present study and is probably more pronounced in patients
with treatment-naive CPPS. The findings of the secondary analyses should be
interpreted cautiously due to their exploratory nature, especially in view of
multiple testing and the limited sample size of our trial. Assessment of therapy
compliance was patient self-reported in an unmonitored setting and data on
compliance was only available for 45 out of 60 included patients, which represents
another limitation of this study. In addition, our results in men cannot be
generalized to women with CPPS. Strengths include concealment of allocation
and strict blinding of patients through the use of coded devices of identical
appearance and an intention to treat analysis.
4.4. Implications for research
Our results indicate that sono-electro-magnetic therapy may be superior with a
clinically relevant difference when compared to placebo intervention, even
though, as it is expected in such patient population and trial design, placebo
effects were important [30]. A larger trial of similar design is required to confirm
or refute our preliminary results, particularly in patients with symptom duration
of 12 months or less. If our results can be confirmed, a pilot trial in women is
warranted in addition.
There are as yet no treatment standards for neuromodulation therapy, and no
guidelines for therapeutic and maintenance regimens, and these must be
developed through further research and testing. The stimulation parameters of
sono-electro-magnetic therapy should be explored because individual adjustment
of the stimulation parameters may improve the response rate, as it has for sacral
neuromodulation. It is also unclear if maintenance-therapy is required to
maintain the gains of treatment in CPPS.
CPPS may modulate spinal cord reflexes and brain networks via peripheral
afferents, but we do not fully understand the mechanisms engaged in initiating
and maintaining CPPS. Clarification of the precise mechanisms of action is
Sono-Electro-Magnetic Treatment of Chronic Pelvic Pain Syndrome
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needed. Direct comparisons of sono-electro-magnetic therapy to percutaneous
tibial nerve stimulation and transcutaneous nerve stimulation, as well as to more
invasive neuromodulation procedures such as sacral and pudendal neuromodu-
lation, will help us understand how CPPS affects body systems. Conducting
neuroimaging studies in patients who undergo CPPS may provide insight into
pain processing mechanisms and eventually answer fundamental questions about
neuroplasticity and the potential reversibility of conditions like CPPS.
4.5. Implications for practice
If our results can be confirmed in larger trials, sono-electro-magnetic therapy
would offer a simple, non-invasive, widely available, inexpensive and effective
approach towards treating patients with treatment refractory CPPS. The
significant interaction with duration of symptoms suggests that patients should be
treated early in the course of the disease.
4.6. Conclusions
Sono-electro-magnetic therapy did not result in a significant improvement of
symptoms in the overall cohort of treatment refractory CPPS patients compared
to placebo treatment. Subgroup analysis indicates, however, that patients with a
symptom-duration of 12 months or less may benefit from sono-electro-magnetic
therapy, warranting larger randomized controlled trials in this subpopulation.
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